ArticleNature2023
Co-transplantation of autologous T
Open access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
17.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Therapeutic Potential of PSC-derived Cell Transplantation in Parkinson's Disease: A Systematic Review and Meta-analysis of Preclinical Studies.Current stem cell research & therapy · 2026Pooled it
- Impact of vitamin D3 supplementation on motor functionality and the immune response in Parkinson's disease patients with vitamin D deficiency.Scientific reports · 2025Trial
- Cell-based immunotherapy for neurodegenerative disease: A promising avenue.Neural regeneration research · 2026Article
- Review
- Gestational Hypoxia Disrupts Medial Ganglionic Eminence Progenitor Dynamics and Interneuron Development in Schizophrenia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Gut-brain axis dysregulation in Parkinson's disease: Mechanisms linking microbiota to neuroinflammation and α-synuclein pathology.Journal of pharmaceutical analysis · 2026Review
- SVF Combined with HGF-Functionalized Self-Assembling Peptide Hydrogel Promotes Spinal Cord Injury Repair in Rats.Gels (Basel, Switzerland) · 2026Article
- Research on stem cell therapy for brain injury: A bibliometric and visual analysis (2009-2025).IBRO neuroscience reports · 2026Review
- Cryopreservable dopaminergic progenitors derived from human iPSCs with accelerated loss of pluripotency and early functional restoration in Parkinsonian rats.NPJ Parkinson's disease · 2026Article
- Selective CaStem cell reports · 2026Article
- Parkinson's disease: pathogenesis and therapeutic strategies.Molecular biomedicine · 2026Review
- Human pluripotent stem cell engineering with CRISPR-Cas9 for Parkinson's disease.Experimental & molecular medicine · 2026Review
- Review
- CAR Treg therapies for neurodegenerative diseases.iScience · 2026Review
- The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: Implications for the STEM-PD clinical trial.Stem cell reports · 2026Article
- Microglia-T cell interactions drive α-synuclein pathology in a Parkinson's disease mouse model.Journal of neuroinflammation · 2026Article
- CD4+T cell metabolic reprogramming as therapeutic targets in neurodegenerative diseases.Molecular brain · 2026Review
- Article
- Olfactory-to-Entorhinal Network Dysrhythmias Drive Parkinson's Cognitive Impairment Through Frequency-Specific Oscillatory Decoupling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Super-resolution ultrasound imaging indirectly reveals neurovascular uncoupling in substantia nigra of a Parkinson's disease model.NPJ Parkinson's disease · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 2 institutions in 2 countries.
Tae-Yoon Park *Molecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA.ORCID 0000-0001-6358-9375
Jeha Jeon *Molecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA.ORCID 0000-0003-3779-2446
Nayeon LeeMolecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA.ORCID 0000-0002-3377-2301
Jisun KimMolecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA.
Bin SongMolecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA.
Jung-Ho KimDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
Sang-Kyou LeeDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
Dongxin LiuMolecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA.ORCID 0000-0002-0956-5142
Young ChaMolecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA.ORCID 0000-0001-7647-0699
Minseon KimMolecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA.ORCID 0000-0002-1193-7937
Pierre LeblancMolecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA.ORCID 0000-0001-8756-2396
Todd M HerringtonDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Bob S CarterDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jeffrey S SchweitzerDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4079-0791
Kwang-Soo KimMolecular Neurobiology Laboratory, Department of Psychiatry and McLean Hospital, Harvard Medical School, Belmont, MA, USA. kskim@mclean.harvard.edu.ORCID 0000-0002-6081-9857
Harvard University · USYonsei University · KR
Funding
Protein-induced human iPS cells for personalized cell therapy of PDR01NS070577 · NINDS · MCLEAN HOSPITAL · PI KIM, KWANG-SOO, KORDOWER, JEFFREY H · 2010 to 2020
$4.9MBiorepository of iPSC lines from diverse rat strains for regenerative medicine researchR24OD024622 · OD · MCLEAN HOSPITAL · PI KIM, KWANG-SOO, KONG, SEK WON · 2018 to 2021
$3.4MHuman iPSC-Based Personalized Cell Therapy of PDR01NS129188 · NINDS · MCLEAN HOSPITAL · PI Kwang-Soo Kim, Sek Won Kong · 2023 to 2026
$2.8MCrosstalk Between Nurr1 and Risk Factors of Parkinson's Disease and its Regulation by Nurr1's LigandsR01NS127391 · NINDS · MCLEAN HOSPITAL · PI Kwang-Soo Kim · 2023 to 2026
$1.8MUsing phasic stimulation to explore the subthalamic nucleus - cortical decision-making network in Parkinson's diseaseK23NS099380 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI HERRINGTON, TODD · 2017 to 2021
$1.0MNIH HHS R24 OD024622NINDS NIH HHS K23 NS099380NINDS NIH HHS R01 NS070577NINDS NIH HHS R01 NS127391NINDS NIH HHS R01 NS129188
Abstract
The specific loss of midbrain dopamine neurons (mDANs) causes major motor dysfunction in Parkinson's disease, which makes cell replacement a promising therapeutic approach
Indexed as
Cell- and Tissue-Based TherapyDopaminergic NeuronsGraft SurvivalNeuroinflammatory DiseasesParkinson DiseaseT-Lymphocytes, RegulatoryTyrosine 3-MonooxygenaseAnimalsCell DeathCell ProliferationDopamineHumansInduced Pluripotent Stem CellsMesencephalonMiceNeostriatumDopamineOxidopamineTyrosine 3-Monooxygenase
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.